De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes

Killick, Sally; Jackson, Aimee; Coulthard, Helen Chantal; Yap, Christina; Das‐Gupta, Emma; Pennell, Dudley J.; Porter, John B.; Bowen, David; Culligan, Dominic

doi:10.1111/bjh.16669

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients receiving regular blood transfusions will inevitably develop iron overload. Although evidence is accumulating for the benefit of iron chelation therapy in MDS patients with transfusion‐related iron overload, 54 there is a paucity of data in AA. The 1‐year Evaluation of Patients' Iron Chelation with Exjade study 55 showed chelation with deferasirox was safe and could reduce the ferritin level.…”

Section: Supportive Carementioning

confidence: 99%

Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline

Kulasekararaj,

Cavenagh,

Dokal

et al. 2024

Br J Haematol

Self Cite

View full text Add to dashboard Cite

SummaryPancytopenia with hypocellular bone marrow is the hallmark of aplastic anaemia (AA) and the diagnosis is confirmed after careful evaluation, following exclusion of alternate diagnosis including hypoplastic myelodysplastic syndromes. Emerging use of molecular cyto‐genomics is helpful in delineating immune mediated AA from inherited bone marrow failures (IBMF). Camitta criteria is used to assess disease severity, which along with age and availability of human leucocyte antigen compatible donor are determinants for therapeutic decisions. Supportive care with blood and platelet transfusion support, along with anti‐microbial prophylaxis and prompt management of opportunistic infections remain key throughout the disease course. The standard first‐line treatment for newly diagnosed acquired severe/very severe AA patients is horse anti‐thymocyte globulin and ciclosporin‐based immunosuppressive therapy (IST) with eltrombopag or allogeneic haemopoietic stem cell transplant (HSCT) from a matched sibling donor. Unrelated donor HSCT in adults should be considered after lack of response to IST, and up front for young adults with severe infections and a readily available matched unrelated donor. Management of IBMF, AA in pregnancy and in elderly require special attention. In view of the rarity of AA and complexity of management, appropriate discussion in multidisciplinary meetings and involvement of expert centres is strongly recommended to improve patient outcomes.

show abstract

Section: Supportive Carementioning

confidence: 99%

Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline

Kulasekararaj,

Cavenagh,

Dokal

et al. 2024

Br J Haematol

Self Cite

View full text Add to dashboard Cite

show abstract

De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes

Abstract: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Cited by 1 publication

References 25 publications

Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline

Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline

Contact Info

Product

Resources

About